HIV envelope protein (Env) is the sole target of broadly neutralizing antibodies (BNAbs) that are capable of neutralizing diverse strains of HIV. While BNAbs develop spontaneously in a subset of HIV-infected patients, efforts to design an envelope protein-based immunogen to elicit broadly neutralizing antibody responses have so far been unsuccessful. It is hypothesized that a primary barrier to eliciting BNAbs is the fact that HIV envelope proteins bind poorly to the germline-encoded unmutated common ancestor (UCA) precursors to BNAbs. To identify variant forms of Env with increased affinities for the UCA forms of BNAbs 4E10 and 10E8, which target the Membrane Proximal External Region (MPER) of Env, libraries of randomly mutated Env variant...
A steady increase in knowledge of the molecular and antigenic structure of the gp120 and gp41 HIV-1 ...
A major challenge in HIV vaccine development is the identification of immunogens able to elicit broa...
A major challenge in HIV vaccine development is the identification of immunogens able to elicit broa...
Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in nat...
The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HI...
SummaryBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) tri...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HI...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
Preventive HIV-1 vaccine strategies rely on the elicitation of broadly neutralizing antibody (bNAb) ...
Preventive HIV-1 vaccine strategies rely on the elicitation of broadly neutralizing antibody (bNAb) ...
Worldwide, over 37 million people are currently infected with rapidly mutating human immunodeficienc...
Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bN...
A steady increase in knowledge of the molecular and antigenic structure of the gp120 and gp41 HIV-1 ...
A major challenge in HIV vaccine development is the identification of immunogens able to elicit broa...
A major challenge in HIV vaccine development is the identification of immunogens able to elicit broa...
Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in nat...
The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HI...
SummaryBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) tri...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HI...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
Preventive HIV-1 vaccine strategies rely on the elicitation of broadly neutralizing antibody (bNAb) ...
Preventive HIV-1 vaccine strategies rely on the elicitation of broadly neutralizing antibody (bNAb) ...
Worldwide, over 37 million people are currently infected with rapidly mutating human immunodeficienc...
Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bN...
A steady increase in knowledge of the molecular and antigenic structure of the gp120 and gp41 HIV-1 ...
A major challenge in HIV vaccine development is the identification of immunogens able to elicit broa...
A major challenge in HIV vaccine development is the identification of immunogens able to elicit broa...